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Abstract
Hyperthyroidism is characterized by increased vascular relaxation and decreased vascular contraction and is associated with
augmented levels of triiodothyronine (T3) that contribute to the diminished systemic vascular resistance found in this
condition. T3 leads to augmented NO production via PI3K/Akt signaling pathway, which in turn causes vascular smooth
muscle cell (VSMC) relaxation; however, the underlying mechanisms involved remain largely unknown. Evidence from
human and animal studies demonstrates that the renin-angiotensin system (RAS) plays a crucial role in vascular function
and also mediates some of cardiovascular effects found during hyperthyroidism. Thus, in this study, we hypothesized that
type 2 angiotensin II receptor (AT2R), a key component of RAS vasodilatory actions, mediates T3 induced-decreased vascular
contraction. Marked induction of AT2R expression was observed in aortas from T3-induced hyperthyroid rats (Hyper). These
vessels showed decreased protein levels of the contractile apparatus: a-actin, calponin and phosphorylated myosin light
chain (p-MLC). Vascular reactivity studies showed that denuded aortic rings from Hyper rats exhibited decreased maximal
contractile response to angiotensin II (AngII), which was attenuated in aortic rings pre-incubated with an AT2R blocker.
Further study showed that cultured VSMC stimulated with T3 (0.1 mmol/L) for 24 hours had increased AT2R gene and
protein expression. Augmented NO levels and decreased p-MLC levels were found in VSMC stimulated with T3, both of
which were reversed by a PI3K/Akt inhibitor and AT2R blocker. These findings indicate for the first time that the AT2R/Akt/
NO pathway contributes to decreased contractile responses in rat aorta, promoted by T3, and this mechanism is
independent from the endothelium.
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Introduction
Thyroid diseases, which are estimated to affect 10% of the
population [1,2] are accompanied by profound cardiovascular
changes. In particular, hyperthyroidism induces a high-output
state, with a marked decrease (up to a 50 percent) in systemic
vascular resistance (SVR), possibly due to local release of
vasodilators in peripheral tissues as a consequence of the elevated
tissue metabolism [3]. The diminished SVR seen in hyperthy-
roidism has been attributed to a direct effect of T3, the biologically
active form of thyroid hormone, on vascular endothelium [4].
However, the underlying mechanisms associated with the T3
actions on the vascular smooth muscle cell (VSMC) are still
unclear. Our group has demonstrated that T3 promoted marked
NO production in VSMC by rapid nongenomic actions, which in
turn contributed to vascular relaxation [5], suggesting the VSMC
as a specific target of T3, which may represent an important factor
for local control of vascular function.
Several lines of evidence suggest an important contribution of
the renin-angiotensin system (RAS) to the actions of the thyroid
hormones (TH) [6–9]. Two isoforms for angiotensin II receptor
have been identified in VSMC: type 1 receptor (AT1R) and type 2
receptor (AT2R) [10,11]. AT2R is upregulated in certain
pathological conditions such as hypertension, vascular injury,
inflammation [12] and also in hyperthyroidism [8]. The AT2R
mediates cellular differentiation and growth, and in some
circumstances opposes the actions of AT1R stimulation [13–15]
and therefore, it is important in reducing tissue remodeling and
disease progression. In addition, AT2R promotes relaxation in rat
isolated resistance arteries and aortas [16,17] via activation of
a vasodilatory cascade involving bradykinin (BK), nitric oxide
(NO), and guanosine cyclic 39,59-monophosphate (cGMP),
counteracting AT1R-induced contraction [18,19].
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Based on evidence that AT2R stimulates NO production [20]
and that NO production is increased in VSMC by nongenomic
action of T3 [5], as well as data showing that thyroid hormone
induces an upregulation of AT2 receptor in cardiac myocytes [8],
we hypothesized that AT2R contributes to the decreased VSMC
contraction observed during hyperthyroidism condition, which
may represent an important mechanism to vascular relaxation
observed in this pathology. In this study we evidenced for the first
time that AT2R/Akt/NO pathway represents a novel mechanism
associated with the decreased VSMC contraction promoted by
thyroid hormone.
Methods
Ethics Statement
All procedures were performed in accordance with the Guiding
Principles in the Care and Use of Animals, approved by Ethics
Committee for Animal Research of the Institute of Biomedical
Sciences, University of Sao Paulo- Brazil and also by Georgia
Health Sciences University Committee on the Use of Animals in
Research and Education published by the US National Institutes
of Health.
Animals and Experimental Procedures
Adult, male Wistar rats weighing 200–260 g were housed under
a temperature-and light-controlled environment (2261uC on
a 12 h light/dark cycle at 60% humidity) and were given free
access to standard rat chow diet and water ad libitum. Rats were
randomized into two groups: control and hyperthyroid (Hyper).
Rats were induced to hyperthyroidism by daily injections of T3
(7 mg/100 g BW in 0.01 mM NaOH, i.p.) for 14 days, while
control rats received a daily injection of vehicle. Unless otherwise
stated, the rats were killed by decapitation 24 h after the last dose
of T3 (Sigma, St Louis, MO). Blood samples were collected in
order to evaluate the serum levels of thyroid hormone (TH) and
confirm the hyperthyroid status of the animals. The ratio between
heart weight (HW) and tibial length (TL) (in mg/mm) was used as
an index of cardiac hypertrophy, usually observed in hyperthyroid
condition.
Thoracic aortas were isolated and used for functional studies
and molecular assays.
Hemodynamic Parameters
To fully characterize our animal model of hyperthyroidism,
body weight (BW) was evaluated daily and indirect systolic blood
pressure (SBP) and heart rate (HR) were determined at the same
time of day by tail-cuff plethysmography (Kent Scientific,
Litchfield, CT). Rats were familiarized with the apparatus for
a total of 7 days before the measurements were taken. The final
determinations of SBP and BW were made immediately before the
animals were sacrificed.
Serum TH Measurements
Trunk blood was collected without anticoagulant, centrifuged at
3,000 rpm for 15 min at 4uC, and stored at 220uC. Levels of free
T3 and thyroxine were determined in the serum of control and
hyper group using a commercial radioimmunoassay kit (CIS Bio
International, Gif-sur-Yvette, France).
Vascular Functional Studies
In one set of experiments, after euthanasia with isoflurane (via
nasal 5% in 100% O2, thoracic aortas were removed and cleaned
from fat tissue in Krebs solution (130 mmol/L NaCl, 14.9 mmol/
L NaHCO3, 4.7 mmol/L KCl, 1.18 mmol/L KH2PO4,
1.17 mmol/L MgSO4-7H2O, 1.56 mmol/L CaCl2-2H2O,
0.026 mmol/L EDTA, 5.5 mmol/L glucose). Aortas were cut
into rings (2 mm in length), were carefully mounted in a myograph
for isometric tension recordings and were equilibrated in Krebs
solution for 30 min, gassed with 5% CO2 in O2 to maintain a pH
of 7.4, as described previously [5]. Aortas rings were placed under
resting tension (30 mN, previously determined) for 1 hour with
frequent buffer changes until equilibrated. In all experiments the
endothelium was mechanically removed by gently rolling the
lumen of the vessel on a thin metallic wire. The absence of the
endothelium was verified using acetylcholine (ACh) in phenyleph-
rine (PE) pre-contracting aortic ring preparations. Aortic rings
producing less than 10% relaxation to Ach were regarded as
indication of successful denudation. Cumulative concentration-
response curves to angiotensin II (Ang II, 0.1 nM - 0.1 mM) were
performed in the absence or presence of AT2R blocker,
PD123319 (0.1 mM, 30 min incubation). This blocker has a high
affinity for AT2R and a low affinity for the AT1R [21].
Cell Cultures
Isolation, characterization and maintenance of cultured rat
aortic VSMC have been previously described [5,22]. Briefly, cells
were maintained in DMEM containing 10% FBS and antibiotics.
After reaching confluence, VSMC were made quiescent by serum-
deprivation for 24 hours and then stimulated with T3 (0.1 mM) for
24 hours. In some experiments cells were pretreated with
PD123319 (0.1 mM) [23], or with Wortmannin (100 nM),
a selective inhibitor of PI3K/Akt [24] for 30 min.
mRNA and Protein Expression
Total RNA from cultured VSMC was isolated with Trizol
Reagent (Invitrogen, CA, USA). For reverse transcription, we
employed 1 mg of total RNA using SuperScript II Reverse
Transcriptase (Invitrogen). Real-time RT-PCR was performed in
a thermocycler (Corbett Research, Sydney, Australia) using the
SYBR Green PCR master mix (Invitrogen) according to the
manufacturer’s recommendations. The following primer se-
quences were used for AT2R: 59- CCT TCT TGG ATG CTC
TGA CC -39 and 59- TGG AGC CAA GTA ATG GGA AC -39,
while those for b-actin were: 59- TAT GCC AAC ACA GTG
CTG TCT GG -39 and 59- TAC TCC TGC TTC CTG ATC
CAC AT -39. Samples were run in duplicate, and the real-time
RT-PCR data were normalized to b-actin, since we have
previously confirmed that variations in TH levels do not alter b-
actin mRNA levels [8].
Immunoblottings were performed as previously described [5].
Extracted protein (30 mg) from aorta or cultured VSMC was
subjected to SDS-PAGE (10%) gel electrophoresis and transferred
to a nitrocellulose membrane. The membranes were incubated
with primary antibodies (Santa Cruz Biotechnology, except for a-
actin, from Sigma) overnight at 4uC and a mouse monoclonal a-
actinin specific antibody was used as an internal control. The
primary antibodies used in this study were against RAS
components (AngI/AngII, AT1R, AT2R), contractile proteins
(a-actin, calponin, p-MLC and Total MLC), and Akt signaling
pathway (Thr308-Akt, Ser473-Akt, Total Akt). Bound proteins were
detected using a chemi-luminescence reaction kit (Amersham
Pharmacia Inc., Uppsala, Sweden).
NO Detection Assay
The release of NO from VSMC stimulated with T3 (0.1 mM)
for 24 hours was measured as nitrite (NO2
2) accumulation in the
culture media and media from untreated VSMC was used as
control, as previously described [25]. The blocker of AT2R or
AT2R Mediates T3-Induced VSMC Relaxation
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PI3K inhibitor (PD123319, 0.1 mM or Wortmannin, 0.1 mM,
respectively), were added 30 minutes before T3 stimulation. We
analyzed the chemi-luminescence reaction between ozone and the
NO generated by reduction of the sample with vanadium chloride
in acid at 95uC using an NO analyzer (Model 208A; Sievers
Instruments Inc., Boulder, CO) according to the manufacturer
protocols. NO2
2 levels were corrected for total protein content of
VSMC extracts determined by Bradford method [26]. The rates of
NO2
2 accumulation were expressed as micromol per gram of
protein.
In other experiments, non destructive NO was detected using
the NO-specific fluorescent dye, 4,5-diaminofluorescein diacetate
(DAF-2, Sigma, St. Louis, MO, USA) as previously reported [5].
VSMC were loaded with DAF-2 (10 mM) for 30 min and then
treated with T3 (0.1 mM) for 24 hours. To investigate the
participation of PI3K/Akt pathway in T3 induced-NO pro-
duction, VSMC were pre-incubated with wortmannin (0.1 mM)
for 30 min. Images were obtained by fluorescence microscope
(Axioskop, Zeiss, Go¨ttigen, Germany). Fluorescence intensity in
each cell was quantified by pixel intensity of the cell using image
software (KS-300 Software, Zeiss). Background subtraction was
performed for each image prior to the quantification. The intensity
of fluorescence is directly proportional to NO concentration
present in the media [27].
Statistical Analysis
All data are expressed as mean 6 SD, unless otherwise
indicated. Contractions were recorded as changes in the displace-
ment (mN) from baseline. Concentration-response curves were
fitted using a nonlinear interactive fitting program (Graph Pad
Prism 4.0; GraphPad Software Inc.), and two pharmacological
parameters were obtained: the maximal effect generated by the
agonist (or Emax) and –log EC50 (or pD2). Statistical analyses were
performed using One-way ANOVA or Student’s test. Post-hoc
comparisons were performed using Bonferroni’s test. Statistical
significance was accepted at p,0.05.
Results
Validation of Hyperthyroidism Experimental Model in
Rats
To determine whether the T3-treated rats were induced
successfully to hyperthyroidism, the serum levels of free T3 and
T4 were measured. Additionally, some of the typical alterations
present in hyperthyroidism [28] such as cardiac hypertrophy,
systolic blood pressure, heart rate, and body weight were also
determined (Table 1). T3-treated rats exhibited increased T3 and
decreased T4 serum levels, which confirms the hyperthyroid
status. Similar to humans, hyperthyroid rats showed an augmented
metabolic condition characterized by decreased body weight and
also tachycardia. T3 treatment led to cardiac hypertrophy
determined by an increase in the heart weight to tibia length
ratio. No changes were observed in systolic blood pressure in
control animals during treatment, while T3 induced a significant
increase (approximately 15%) after 14 days of treatment. Taken
together these results confirm the efficiency of T3 treatment
inducing hyperthyroidism in these rats.
T3-treatment Decreases Contractile Protein Levels in
Aortas
One likely explanation for the vascular relaxation present in
hyperthyroidism is a reduction in proteins related to smooth
muscle contraction. Indeed, phosphorylated MLC levels (p-MLC),
a well-known marker of contraction, were decreased by 30% in
aortas from T3-treated rats compared to vehicle treated
(Figure 1A). Moreover, decreased expression of a-actin and
calponin, both essential proteins in the contractile mechanism of
smooth muscle, were observed in the aortas from T3-treated rats
(Figure 1B).
T3-treatment Promotes Upregulation of AT2R
Since it has been demonstrated that AT2R play a physiological
role in the hypertrophy of cardiac myocytes under hyperthyroid-
ism conditions [8] and because AT2R is directly associated with
the production of the vasodilatory cascade composed by
bradykinin, nitric oxide and guanosine cyclic 39,59-monopho-
sphate (cGMP) that mediates vasodilatation [18,29] we evaluated
the AngI/AngII and AT2R levels in aortas from hyperthyroid
animals. Hyper group presented a significant upregulation of
AT2R expression (Figure 1C) and increased local AngI/AngII
levels compared to control (Figure 1D).
T3-treatment Decreases Contraction to Ang II in the
Aorta via AT2R
In order to determine whether the upregulation of AT2R
contributes to T3-induced relaxation, concentration-response
curves to angiotensin II (Ang II) were performed in endotheli-
um-denuded aortic rings from Hyper and control rats, in the
presence or absence of PD123319, a specific AT2R blocker. Ang
II produced concentration-dependent contraction in all tested
aortic rings. Aortas from Hyper rats displayed decreased
contraction to Ang II compared with control aortas (Emax
6.7360.37 vs. 15.260.56 mN, p,0.05, respectively) and this
effect was attenuated in the aortas pre-incubated with PD123319
(12.4560.41 mN, p,0.05) (Figure 2). No differences were
observed in the pD2 among the groups. These data suggest
AT2R is involved in decreased contraction to AngII in hyperthy-
roid rats.
T3 Increases AT2R Gene and Protein Expression Levels in
Cultured VSMC
Based on the effects of hyperthyroidism on AT2R expression in
aortas, we examined the effect of T3 treatment in cultured VSMC.
The AT2R mRNA levels were significantly increased in a T3
concentration-dependent manner (from 0.001 mM to 1.0 mM)
(Figure 3A). Further, VSMC stimulated with T3 (0.1 mM) for 24
Table 1. Experimental groups at baseline and after 14 days of
T3-treatment.
Co Control Hy Hyperthyroid
Parameter 0 Day 14 Days 0 Day 14 Days
Body weight (g) 271.569.8 368.3616.8 268.5614.2
272.1612.4*
SBP (mmHg) 121.366.2 126.667.1 123.666.3 139.767.7*
HR (beats/min) 374617 383615 372620 448612*
HW/TL (mg/mm) 18.861.3 28.662.1*
Free T3 (ng/ml) 0.4260.11 1.3160.56*
Free T4 (ng/ml) 31.963.35 8.860.68*
Values are expressed as mean 6 SD; n = 12 per group. BP indicates blood
pressure; HW, heart weight; BW, body weight; TL, tibial length; T3,
triiodothyronine; T4, thyroxine.
*p,0.05, vs. Control.
doi:10.1371/journal.pone.0061982.t001
AT2R Mediates T3-Induced VSMC Relaxation
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Figure 1. Effect of Hyperthyroidism (Hyper) in the protein expression. Hyper reduced the expression of contractile proteins: p-MLC (A), a-
actin and calponin (B). In addition, Hyper was associated with increased AT2R (C) and AngI/II (D) levels in aortas. Top: representative blots. Bottom:
Densitometry values. Data are expressed as mean 6 SD (n = 6) per group, *p,0.05 vs. control.
doi:10.1371/journal.pone.0061982.g001
AT2R Mediates T3-Induced VSMC Relaxation
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hours showed augmented AT2R and unchanged AT1R protein
expression (Figure 3B), which was accompanied by increased
AngI/II levels (Figure 3C). These results indicate that T3 plays
important role in local activation of RAS.
AT2R Mediates the T3-induced Diminution of Contractile
Protein Expression in Cultured VSMC
In order to investigate whether AT2R contributes to T3-
induced vascular relaxation, cells were treated for 24 hours with
T3 (0.1 mM) and/or pre-incubated with AT2R blocker. T3
induced a significant decrease in p-MLC and a-actin levels in
cultured VSMC, which was partially reversed in cells pre-
incubated with PD123319 for 30 min. These data support the
previous results found in aortas from T3-treated rats and also show
that the direct effect of T3 in diminishing the contractile apparatus
proteins is mediated by AT2R (Figure 4).
T3-induced NO Production Occurs via AT2R/Akt Pathway
We previously reported that T3 rapidly stimulates NO pro-
duction in VSMC [5]. Using nitrite (NO22) levels assay, we
observed that the levels of NO22 were augmented by 2 fold in
supernatants of cultured VSMC stimulated with T3. This effect
was diminished in cells pre-incubated with PD123319 (Figure 4C).
Because the PI3K/Akt signaling pathway is downstream of AT2R
[30] and is involved in the vascular NO production [24], we next
examined the effects of wortmannin (W), a selective inhibitor of
PI3K, in T3-induced NO production. The increased levels of NO
in VSMC stimulated with T3 were partially reversed in the
presence of wortmannin (Figure 4D). To confirm whether T3-
induced PI3K/Akt activation occurs via AT2R, we measured
activation of PI3K/Akt by phosphorylation in the presence of
PD123319. We observed increased levels of phosphorylation Akt
at Ser473 and Thr308 in VSMC stimulated with T3; however, in
the presence of PD123319, this effect was reduced, showing that
T3 activates PI3k/Akt signaling via AT2R (Figure 5). Together
these results support the hypothesis that T3 stimulates AT2R in
VSMC, which in turn activates PI3k/Akt signaling pathway that
triggers NO production leading to vascular relaxation. Thus, we
Figure 2. AT2R mediates endothelium-independent decreased
contraction in aortas from hyperthyroid rats. Contractile re-
sponse to AngII (from 0.1 nM to 0.1 mM) is decreased in hyper
denuded-aortas (open square) when compared to control group (open
circle). The specific blockade of AT2R with 0.1 mM PD123319 (filled
square) reverses this effect when compared to control group pretreated
with PD (filled circle). Data are represented as mean 6 SEM (n = 4 per
group, *p,0.05 vs. control group, #p,0.05 vs. control+PD).
doi:10.1371/journal.pone.0061982.g002
Figure 3. T3 upregulates AT2R in VSMC. Concentration-dependent
T3-induced increased AT2mRNA in cultured VSMC (A).VSMC treated
with T3 (0.1 mm) for 24 hours leaded to an increased AT2R (B) and AngI/
AT2R Mediates T3-Induced VSMC Relaxation
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propose a new model to explain the decreased vascular
contraction observed in the hyperthyroidism (Figure 6).
Discussion
The novel finding of the current study was that AT2R present
in VSMC plays a key role in the hyperthyroidism-induced
decrease in contractile response accompanied by an increase in
Akt/NO pathway signaling. This is based on the following results:
a) Decreased contractile response to AngII in denuded aortas from
hyperthyroid rats was attenuated by AT2R blocker; b) Decreased
II (C) protein expression. Data represent mean 6 SD in %, considering
the control situation as 100% (n = 5 per group, *p,0.05 vs. control).
doi:10.1371/journal.pone.0061982.g003
Figure 4. AT2R blocker reduces T3-induced decreased levels of contractile proteins and attenuates T3-induced NO production.
Decreased levels of p-MLC (A) and a-actin (B) in VSMC treated with T3 (0.1 mM) for 24 h were attenuated in the VSMC pre-incubated with PD123319
(0.1 mM) for 30 min. Pre-incubation with PD123319 (0.1 mM) (C) and wortmannin (0.1 mM) (D) attenuates the T3-induced augmented NO generation
in VSMC. In (C), NO2
2 concentration was measured by chemiluminescence, while in (D) NO production was determined was determined using the
NO-specific fluorescent dye 4,5-diaminofluorescein diacetate (DAF-2). Data are expressed as mean6 SD (n = 5 per group for A and B; n = 4 per group
for C and D; *p,0.05 vs. control, #p,0.05 vs. T3, $p,0.05 vs. PD).
doi:10.1371/journal.pone.0061982.g004
AT2R Mediates T3-Induced VSMC Relaxation
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vascular contraction during hyperthyroidism was associated with
increased levels of NO and activation of PI3K/Akt, both of which
were attenuated through use of an AT2R blocker.
Unlike the well-known contribution of endothelium on vascular
relaxation in hyperthyroidism [4,31], there is a paucity of data on
the role of VSMC in this field. Since thyroid hormone receptors
(TLRs, TR-alpha and beta) have been identified in the coronary
and aorta from human VSMC [32], the key question raised by
these findings is whether TH has a direct effect in VSMC.
We recently showed that T3 rapidly leads to augment NO
production in VSMC via PI3K/Akt pathway [5]; however the
underlying mechanisms involved are still unknown. In addition,
we and others investigators have previously demonstrated that
cardiovascular actions promoted by TH occur with participation
of local RAS [33,34]. RAS is one of the most important regulators
of vascular function and AT2R represents a crucial component
responsible for vasodilation. Considering the possibility that AT2R
might act as an upstream effector of NO production which in turn
leads to decreased vascular contraction under hyperthyroidism
condition, we hypothesized that AT2R in VSMC mediates the
diminished vascular contraction in hyperthyroidism.
Herein, we used an experimental model of hyperthyroidism, in
which the animals received daily an i.p. injection of T3 (20-fold the
physiological dose) for 14 days. Initially, we confirmed the
hyperthyroid status of the animals, who presented with a significant
increase in heart rate. The tachycardia observed in hyperthyroid-
ism occurs in part due to higher sensitivity of the cardiac tissue to
catecholamines, since T3 induces an increase of b-adrenergic
receptor expression [35–37]. Also, the positive chronotropic effect
of TH is associated with altered expression of ion channels/
transporters in the heart, such as Kv1.5, Kv4.2, hyperpolarization-
activated cyclic nucleotide-gated channel 2 (HCN2), HCN4, Na-
Ca2+ exchanger, and Na+-K+-ATPase [38–40]. As expected,
systolic blood pressure (SBP) levels were increased in hyperthyroid
animals, corroborating data of literature [41]. Consistent with the
decrease in SVR observed in hyperthyroidism, we investigated the
expression of contractile proteins in endothelium-denuded aorta
from T3-treated animals. Aortas from hyperthyroid animals
showed a significant decrease of phosphorylated myosin light
chain (p-MLC) levels, a marker of vascular contractile status
[42,43]. Similarly, alpha-actin and calponin, essential proteins of
contractile vascular machinery [44,45], exhibited a significant
reduction, indicating that hyperthyroidism alters the levels of these
proteins and may contribute to changes in vascular tone leading to
an increased vascular relaxation.
AT2R-mediated vasodilatation has been reported in both
endothelium-dependent and independent manners [18,19,46,47].
Based on AT2R upregulation observed in cardiomyocytes from
the hearts of rats induced to hyperthyroidism [8] we evaluated the
possible involvement of this receptor in VSMC with increased
vascular relaxation observed in this pathology. We observed
increased levels of AT2R in the aortas from hyperthyroid animals,
corroborating with our initial hypothesis that AT2R might be
involved in vascular relaxation found in hyperthyroidism. In
addition, AngI/AngII protein expression levels were also signifi-
cantly increased in aortas from hyperthyroid animals, indicating
that T3 also increased the levels of the ligand AngII. The action of
TH increasing local Ang II levels has already been described in
other cell types [8,9].
We also assessed the direct effect of T3 on cultured VSMC in
order to investigate the possible molecular mechanisms involved in
hormone action on relaxation response. According to the
observations in endothelium-denuded aortas, AT2R was present
under basal conditions in VSMC and its mRNA and protein
expression levels were upregulated after T3 treatment with no
changes on AT1R levels. Similarly, treatment of VSMC with T3
promoted a reduction in p-MLC levels in parallel with a decrease
on alpha-actin levels, confirming the effect of T3 on reducing
contractile proteins. This effect of TH on the contractile protein
levels in VSMC has not been demonstrated previously in the
literature. Taking into account recent evidence showing that
AT2R stimulation could act on the contractile machinery
modulating processes such as depolymerization of actin [48], we
tested the hypothesis of a possible correlation between upregula-
tion of AT2R and decreased contractile proteins found in VSMC
stimulated with T3. Interestingly, VSMC treated previously with
AT2R blocker (PD123319) partially reversed the effect of T3,
showing for the first time an involvement of this receptor in the
action of T3 in the reduction of contractile proteins, possibly to
increase the vascular relaxation found in the hyperthyroidism.
Based on results obtained in vitro we performed functional
studies using vascular reactivity experiments in order to evaluate
the role of AT2R on relaxation induced by T3. Endothelium-
denuded aorta rings from hyperthyroid animals presented a lower
response to Ang II, compared to control. This effect was partially
reversed when the rings were pre-incubated with PD123319,
indicating that the lower contractile response occurs at least in part
to the involvement of AT2R. In fact, previous studies demon-
strated that AT2R located in smooth muscle may directly mediate
vasodilatation effects, but also may minimize the contraction
promoted by Ang II [49]. Besides the morphological arrangement
and all the vessel contractile components, aorta is responsive to
numerous vascular modulators including TH, which makes it
Figure 5. AT2R mediates T3-induced PI3K/Akt activation.
Cultured VSMC stimulated with T3 (0.1 mM for 24 hours) display
increased levels of p-Akt in both residues (thr308 and ser473), which is
partially reversed by the specific blockade of AT2R with PD123319
(0.1 mM for 30 min prior to T3 treatment). Data are expressed as mean
6 SD (n = 6 per group, *p,0.05 vs. control, #p,0.05 vs. T3).
doi:10.1371/journal.pone.0061982.g005
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a good model to study vascular contractile or relaxation
phenomena. In addition, this vessel serves as an important tool
to obtain primary cultures of VSMC [50].
One of the mechanisms by which AT2R promotes vasodilata-
tion is through nitric oxide production (NO) [18,29], which seems
to occur after stimulation of bradykinin by AT2R [51,52]. Thus,
an assay to indirectly evaluate the NO levels through the nitrite
concentrations determination [25] was performed in cultured
VSMC submitted to T3 treatment in the presence or absence of
AT2R blocker. T3 promoted an increase in nitrite concentration
which was partially reversed after pretreatment with the AT2
blocker. Increased vascular NO production has been reported in
rats in hyperthyroid states or after treatment with T3 for 3–4
months [4]. In addition, both nNOS and eNOS have been
identified as targets for the actions of TH [53].
Based on studies showing activation of Akt signaling by TH in
other cell types [9] and a non-genomic effect of TH in increasing
NO levels [5], we also found impairment in the NO production
induced by T3 when an Akt inhibitor (wortmannin) was used. It
has been recently demonstrated that the Akt pathway, classically
activated by AT1R [54], may also be stimulated upon AT2R
activation [30]. In the present study we showed that the AT2R
blockade partially prevented the increase on Akt phosphorylation
levels promoted by T3. Although we didn’t have analyzed which
NOS is involved in this process, it is possible that T3-induced NO
production by VSMCs may occur with expressive participation of
inducible and neuronal NOS as showed previously [5].
In summary, this study demonstrated by in vivo and in vitro
assays a novel mechanism associated with the decreased vascular
contraction promoted by thyroid hormone demonstrating a role of
AT2R/Akt/NO pathway. We showed in the present study an
interaction between TH and vascular RAS mediating vascular
function.
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